QS-Hydroxyurea
127-07-1
CH4n2o2
204-821-7
Negotiable
Normal
>12 Months
Hydroxyurea
Hydroxyurea
>99%
Hydroxyurea
Hydroxyurea Powder
White Powder
White
Veterinary Grade
>99%
API
COA
HPLC
1.457
CH4n2o2
76.05466
142c
136.04c
88.1c
QS-Hydroxyurea
Negotiable
>99%
Xi`an
Product Description

Best Selling Hydroxyurea Pharmaceutical Hydroxyurea



Product Name | Hydroxyurea |
Appearance | Hydroxyurea Powder |
Assay | >99% |
MW | 76.05466 |
MF | CH4N2O2 |
Melting point | 142C |
Density | 1.457 |

Hydroxyurea is an antimetabolite anticancer drug that primarily targets proliferating cells during the G1 and S phases of the cell cycle, delaying the G1/S interface. It is a cell cycle-specific agent with significant antitumor properties. The drug works by inactivating ribonucleotide reductase through the formation of free nitric oxide, which binds to tyrosine residues at the enzyme's active site. This inhibition prevents the synthesis of deoxynucleotides, essential for DNA replication and repair, thereby halting the growth of cancer cells.
Hydroxyurea is clinically used in the treatment of chronic myelogenous leukemia, metastatic ovarian cancer, primary squamous cell carcinoma of the head and neck, and refractory psoriasis. As an antitumor drug, it plays a crucial role in managing these conditions by selectively targeting rapidly dividing cells and disrupting their proliferation. Its mechanism of action and therapeutic applications make it a valuable option in oncology and dermatology.








